The Shigella flexneri 2a SC602 vaccine candidate carries deletions of the plasmid-borne
virulence gene icsA (mediating intra-and intercellular spread) and the chromosomal locus …

Background Approximately 164,000 deaths yearly are due to shigellosis, primarily in
developing countries. Thus, a safe and affordable Shigella vaccine is an important public …

Glycoconjugate vaccines, in which a cell surface carbohydrate from a micro-organism is
covalently attached to an appropriate carrier protein are proving to be the most effective …

Renewed awareness of the substantial morbidity and mortality that Shigella infection causes
among young children in developing countries, combined with technological innovations in …

Worldwide, enteric infections rank third among all causes of disease burden, being
responsible for some 1.7–2.5 million deaths per year, mostly in young children and infants in …

Shigellosis remains a major public health problem around the world; it is one of the leading
causes of diarrhoeal disease in low-and middle-income countries, particularly in young …

Our development of vaccines to prevent shigellosis is based on the hypothesis that a critical
(protective) level of serum IgG to the O-specific polysaccharide (O-SP) domain of Shigella …

Glycoconjugate vaccines have proven their worth in the protection and prevention of
infectious diseases. The introduction of the Haemophilus influenzae type b vaccine is the …

Background Shigellosis accounts for substantial morbidity and mortality worldwide and is
the second most common cause of moderate and severe diarrhoea in children. Methods …

BACKGROUND: Despite its high worldwide morbidity and mortality, there is yet no licensed
vaccine for shigellosis. We reported the safety and immunogenicity of Shigella O-specific …